1. ATIM-01. NIVOLUMAB AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA; A TRANSLATIONAL TRIAL IN PROGRESS. (11th November 2019) Authors: Eibye, Simone; Hasselbalch, Benedikte; Marie Svane, Inge; Reker Hadrup, Sine; Rønn Olsen, Lars; Skjoeth-Rasmussen, Jane; Scheie, David; Østrup, Olga; Skovgaard Poulsen, Hans; Lassen, Ulrik Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CTIM-22. NIVOLUMAB AND BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA; T-CELL REACTIVITY AGAINST AUTOLOGOUS TUMOR CELLS. (12th November 2021) Authors: Maarup, Simone; Skadborg, Signe; Borch, Annie; Draghi, Arianna; Hasselbalch, Benedikte; Østrup, Olga; Scheie, David; Skjoeth-Rasmussen, Jane; Law, Ian; Svane, Inge Marie; Poulsen, Hans; Hadrup, Sine; Lassen, Ulrik Journal: Neuro-oncology Issue: Volume 23: Supplement 6(2021) Page Start: vi54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. EPID-06. IMMUNE-RELATED PLASMA BIOMARKERS IN GLIOBLASTOMA. (11th November 2019) Authors: Bjørnbak Holst, Camilla; Jarle Christensen, Ib; Skjoeth-Rasmussen, Jane; Skovgaard Poulsen, Hans; Hamerlik, Petra; Sidenius Johansen, Julia Journal: Neuro-oncology Issue: Volume 21(2019)Supplement 6 Page Start: vi75 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗